Regeneron Pharmaceuticals (REGN) Share-based Compensation (2009 - 2026)

Regeneron Pharmaceuticals has reported Share-based Compensation for 18 years, with the latest figure at $257.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 0.66% year-over-year to $257.4 million; the trailing twelve-month figure through Mar 2026 stood at $995.4 million (down 1.29% YoY), and the FY2025 full-year result was $993.7 million, up 1.11% from the prior year.
• Share-based Compensation for Q1 2026 stood at $257.4 million, up from $249.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $304.4 million in Q4 2024, with the low at $159.8 million in Q2 2022.
• Average Share-based Compensation over 5 years is $226.1 million, with a median of $232.0 million recorded in 2022.
• Year-over-year, Share-based Compensation surged 43.02% in 2023 and decreased 18.1% in 2025.
• Tracing REGN's Share-based Compensation over 5 years: stood at $232.0 million in 2022, then grew by 3.62% to $240.4 million in 2023, then climbed by 26.62% to $304.4 million in 2024, then declined by 18.1% to $249.3 million in 2025, then advanced by 3.25% to $257.4 million in 2026.
• The last three Share-based Compensation figures came in at $257.4 million (Q1 2026), $249.3 million (Q4 2025), and $237.0 million (Q3 2025), per Business Quant data.

Peer Comparison